CELL LINEAGE, CELL MATURITY AND BCR-ABL: FACTORS WHICH INFLUENCE IMATINIB UPTAKE IN CHRONIC MYELOID LEUKAEMIA

Jane Engler

The Melissa White Laboratory
Department of Haematology
Centre for Cancer Biology
SA Pathology (IMVS)
Adelaide, Australia

&

Faculty of Health Sciences
Department of Medicine
The University of Adelaide
Adelaide, Australia

A thesis submitted to the University of Adelaide
in candidature for the degree of Doctor of Philosophy
March 2011
candor dat viribus alas  
(Sincerity gives wings to strength)

ipsa scientia potestas est  
(Knowledge itself is power)

prefer et obdura; dolor hic tibi proderit olim  
(Be patient and tough; some day this pain will be useful to you)

aut viam inveniam aut faciam  
(I'll either find a way or make one)

per aspera ad astra  
(Through adversities to the stars!)
DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Jane Engler and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. I also give permission for the digital version of my thesis to be made available on the web, via the University’s digital research repository, the Library catalogue, the Australasian Digital Theses Program (ADTP) and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Jane Engler

March 2011
# TABLE OF CONTENTS

1 INTRODUCTION ................................................................................................................... 1  
1.1 Haematopoiesis .............................................................................................................. 2  
1.1.1 The hierarchy of haematopoiesis ........................................................................... 2  
1.1.2 Regulation of haematopoiesis ................................................................................ 2  
1.1.3 Haematopoietic malignancies ................................................................................ 3  
1.2 Chronic Myeloid Leukaemia ......................................................................................... 3  
1.2.1 Clinical features ..................................................................................................... 3  
1.2.2 Molecular pathogenesis of CML ........................................................................... 4  
1.2.2.1 BCR-ABL kinase activity .............................................................................. 5  
1.2.3 Historical therapies for CML ................................................................................. 6  
1.3 Tyrosine Kinase Inhibitors............................................................................................. 6  
1.3.1 Imatinib ................................................................................................................. .7  
1.3.1.1 Efficacy .............................................................................................................. 7  
1.3.1.2 Resistance .......................................................................................................... 8  
1.3.2 Second Generation Tyrosine Kinase Inhibitors ..................................................... 9  
1.3.2.1 Nilotinib ............................................................................................................. 9  
1.3.2.2 Dasatinib ............................................................................................................ 9  
1.4 Primary Resistance to Imatinib.................................................................................... 10  
1.4.1 Inadequate BCR-ABL kinase inhibition.............................................................. 10  
1.4.2 Intracellular concentration of imatinib .................................................................. 11  
1.5 Efflux Transporters ...................................................................................................... 12  
1.5.1 ABCB1 ................................................................................................................. 12  
1.5.2 ABCG2 ................................................................................................................ 13  
1.5.3 ABCB1 and ABCG2 transcript levels ................................................................. 13  
1.5.3.1 ABCB1 and ABCG2 polymorphisms.............................................................. 14  
1.6 Influx Transporters....................................................................................................... 14  
1.6.1 Organic cation transporter 1 (OCT-1) ................................................................. 15  
1.6.1.1 OCT-1 transcript levels .................................................................................... 16  
1.6.1.2 OCT-1 polymorphisms .................................................................................... 17  
1.6.1.3 OCT-1 activity ................................................................................................. 17  
1.7 Disease Persistence ...................................................................................................... 18  
1.7.1 Leukaemic stem cells........................................................................................... 18  
1.7.2 Methods of resistance .......................................................................................... 19  
1.8 Summary and Project Aims ......................................................................................... 20  
2 MATERIALS AND METHODS............................................................................................ 21  
2.1 Commonly Used Reagents........................................................................................... 22  
2.2 Solutions, Buffers & Media ......................................................................................... 23  
2.2.1 Blocking buffer .................................................................................................... 23  
2.2.2 Cell culture media ............................................................................................... 23  
2.2.3 dNTP set (N = A, C, G, T) ................................................................................... 23  
2.2.4 Flow cytometry fixative (FACS Fix) ................................................................... 24  
2.2.5 Freeze mix ............................................................................................................ 24  
2.2.6 Hanks Balanced Salt Solution (Hanks) .............................................................. 24  
2.2.7 Imatinib mesylate, MW = 589.72 ........................................................................ 24
2.2.8 50% [14C]- Imatinib (100µM) .............................................................. 24
2.2.9 Ko143 – inhibits ABCG2 .............................................................................. 25
2.2.10 Laemmlis’s buffer ...................................................................................... 25
2.2.11 MACS buffer ............................................................................................. 25
2.2.12 2.5% Membrane blocking solution ............................................................ 25
2.2.13 Nilotinib, MW = 529.5 ................................................................................ 26
2.2.14 50% [14C]-Nilotinib .................................................................................... 26
2.2.15 Percoll (ρ = 0.99g/mL) ................................................................................ 26
2.2.16 Prazosin hydrochloride - inhibits OCT-1.................................................... 26
2.2.17 PSC833 – inhibits ABCB1 .......................................................................... 26
2.2.18 Random Hexamer Primer (100mg stock) .................................................. 26
2.2.19 SDS-Polyacrylamide Gel .......................................................................... 27
2.2.20 1 x TBS ....................................................................................................... 27
2.2.21 1 x TBST ................................................................................................... 27
2.2.22 Thaw solution ............................................................................................ 27
2.2.23 White cell fluid .......................................................................................... 28
2.3 General Techniques .......................................................................................... 28
2.3.1 Lymphoprep isolation of mononuclear cells (MNC) ..................................... 28
2.3.2 Percoll isolation of monocytes ...................................................................... 28
2.3.2.1 Magnetic Cell Sorting (MACS)................................................................. 29
2.3.2.2 CD3, CD14, CD15 & CD16 Staining ......................................................... 29
2.3.2.3 CD34 Staining .......................................................................................... 29
2.3.2.4 Magnetic Separation ............................................................................... 29
2.3.3 Fluorescence Activated Cell Sorting (FACS) ................................................ 30
2.3.3.1 For CD15/CD16 CML cells ...................................................................... 30
2.3.3.2 For CD34+/CD38- CML cells ................................................................... 30
2.3.4 Antibody staining for Flow Cytometric analysis ........................................... 31
2.3.5 Cryopreservation of cells .......................................................................... 31
2.3.6 Thawing of cells ........................................................................................ 32
2.3.7 Cell counts and viability .............................................................................. 32
2.3.8 Maintenance of cell lines ............................................................................ 32
2.4 Specialised Techniques .................................................................................... 33
2.4.1 Imatinib/nilotinib Intracellular Uptake and Retention (IUR) assay ................ 33
2.4.1.1 OCT-1 activity .......................................................................................... 33
2.4.2 Real Time Quantitative PCR (RQ-PCR) ...................................................... 34
2.4.2.1 RNA extraction ....................................................................................... 34
2.4.2.2 cDNA synthesis ...................................................................................... 34
2.4.2.3 RQ-PCR for transporter mRNA expression ........................................... 35
2.4.2.4 RQ-PCR for BCR-ABL mRNA expression ............................................. 36
2.4.3 Western Blot for phosphorylated CrkI (p-CrkI) ........................................... 37
2.4.4 BCRABL gene transduction in HL60 cell line ............................................. 38
2.4.4.1 Viral vector construction ....................................................................... 38
2.4.4.2 Viral transduction of the HL60 cell line .................................................. 39
2.4.4.3 FACS sorting for GFP+ .......................................................................... 39
2.5 Statistical Analyses ........................................................................................ 39
3 THE RELATIONSHIP BETWEEN CELL LINEAGE AND OCT-1 ACTIVITY .......... 41
3.1 Introduction ..................................................................................................... 42
3.1.1 Approach................................................................. 45

3.2 Results................................................................. 50
3.2.1 Imatinib intracellular uptake and retention (IUR) and OCT-1 activity in CML and normal MNC ................................................................. 50
3.2.2 Immunophenotyping and morphological analysis of the MNC population ........ 50
3.2.3 Isolation of neutrophils, monocytes and lymphocytes from CML patients and normal donors ................................................................. 51
3.2.4 Imatinib intracellular uptake and retention (IUR) and OCT-1 activity in diagnosis CML cell populations ................................................................. 52
3.2.5 BCR-ABL mRNA expression in diagnosis CML cell populations ..................... 53
3.2.6 Imatinib intracellular uptake and retention (IUR) and OCT-1 activity in remission CML cell populations ................................................................. 53
3.2.7 Imatinib intracellular uptake and retention (IUR) and OCT-1 activity in normal cell populations ................................................................. 54
3.2.8 Relationship between OCT-1 activity in MNC and in neutrophils, monocytes and lymphocytes ................................................................. 54
3.2.9 Imatinib intracellular uptake and retention (IUR) and OCT-1 activity between CML diagnosis, CML remission and normal individuals ............ 55
3.2.10 OCT-1 mRNA expression in CML and normal cell populations ..................... 55
3.2.11 ABCB1 mRNA expression in CML and normal cell populations ..................... 56

3.3 Discussion................................................................. 57

4 THE ROLE OF CELL COMPOSITION IN MNC ON A PATIENT’S OCT-1 ACTIVITY .... 61
4.1 Introduction................................................................. 62
4.1.1 Approach................................................................. 64
4.2 Results................................................................. 68
4.2.1 Expression of CD15 and CD16 on MNC from CML patients ..................... 68
4.2.2 Intracellular uptake and retention (IUR) and OCT-1 activity in CD15/CD16 isolated populations in CML patients ................................................................. 68
4.2.3 OCT-1, ABCB1 and BCR-ABL mRNA expression in CD15/CD16 isolated populations in CML patients ................................................................. 69
4.2.4 Relationship between CD15/CD16 expression and MNC OCT-1 activity ......... 69
4.2.5 OCT-1 activity in fresh and thawed MNC ..................................................... 70
4.2.6 CD15/CD16 expression in fresh and thawed MNC .............................................. 70
4.2.7 Relationship between CD15/CD16 expression and thawed MNC OCT-1 activity .... 71

4.3 Discussion................................................................. 73

5 THE EFFECT OF BCR-ABL AND IMATINIB ON OCT-1 ACTIVITY ......................... 76
5.1 Introduction................................................................. 77
5.1.1 Approach................................................................. 78
5.2 Results................................................................. 80
5.2.1 Effect of BCR-ABL on OCT-1................................................................. 80
5.2.1.1 BCR-ABL and p-Crkl expression in HL60 cell lines .............................................. 80
5.2.1.2 Intracellular uptake and retention (IUR), OCT-1 activity and efflux in HL60 cell lines .... 80
5.2.1.3 OCT-1 and ABCB1 mRNA expression in HL60 cell lines .............................................. 81
5.2.2 Effect of granulocyte differentiation on OCT-1 ..................................................... 81
5.2.2.1 Assessment of the degree of differentiation ..................................................... 81
5.2.2.2 IUR, OCT-1 activity and OCT-1 mRNA ................................................................. 82
5.2.3 Effect of monocyte differentiation on OCT-1 ....................................................... 83
  5.2.3.1 Assessment of the degree of differentiation ..................................................... 83
  5.2.3.2 IUR, OCT-1 activity and OCT-1 mRNA ................................................................. 83
5.2.4 Effect of imatinib treatment on OCT-1 ................................................................. 84
  5.2.4.1 P-Crkl and BCR-ABL mRNA expression ....................................................... 84
  5.2.4.2 Proliferation ..................................................................................................... 85
  5.2.4.3 IUR and OCT-1 activity .................................................................................. 85
  5.2.4.4 OCT-1 and ABCB1 mRNA expression ........................................................... 86
5.3 Discussion ................................................................................................................. 87

6 THE EFFECT OF CELL MATURITY ON OCT-1 ACTIVITY .............................................. 91
6.1 Introduction ........................................................................................................... 92
  6.1.1 Approach .............................................................................................................. 94
6.2 Results ................................................................................................................... 97
  6.2.1 Imatinib intracellular uptake and retention (IUR) in CML and normal CD34+ and CD34- cells ........................................................................................................................................... 97
  6.2.2 OCT-1 activity in CML and normal CD34+ and CD34- cells ........................................ 97
  6.2.3 Intracellular uptake and retention (IUR) of imatinib and OCT-1 activity in CML CD34+38- cells .......................................................................................................................... 98
  6.2.4 OCT-1 mRNA expression in CML and Normal CD34+ and CD34- cells ............... 98
  6.2.5 Efflux of imatinib in CML CD34+ cells .................................................................. 99
  6.2.6 Intracellular uptake of nilotinib into CML CD34+ and CD34- cells ...................... 99
  6.2.7 Relationship between MNC and CD34+ OCT-1 activity in CML patients ............ 99
  6.2.8 MNC OCT-1 activity and achievement of major molecular response (MMR) .... 100
  6.2.9 CD34+ OCT-1 activity and achievement of major molecular response (MMR) .... 101
6.3 Discussion ................................................................................................................. 103

7 DISCUSSION .................................................................................................................109
7.1 Major Findings ........................................................................................................ 110
  7.1.1 Biological parameters underlying primary resistance to imatinib therapy .......... 110
  7.1.2 Prediction of primary resistance to imatinib therapy ............................................ 113
  7.1.3 The role of OCT-1 in disease persistence .......................................................... 115
7.2 Summary ................................................................................................................ 117
7.3 Future Directions .................................................................................................. 119
7.4 Conclusion .............................................................................................................. 119

8 REFERENCES ..............................................................................................................120
Manuscripts


Conference Abstracts

JR Engler, C Bailey, J Rasko, AC Zannettino, DL White & TP Hughes. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. *New Directions in Leukaemia Research,* March 2010. Sunshine Coast, Australia. Poster Presentation.

JR Engler, A Frede, V Saunders, AC Zannettino, R D’Andrea, TP Hughes & DL White. CML CD34+ cells have reduced uptake of imatinib due to uniformly low OCT-1 activity, which can be increased with diclofenac treatment. *Centre for Stem Cell Research Annual Meeting*, November 2009. Adelaide, Australia. Poster Presentation.


SCHOLARSHIPS & AWARDS

Poster Prize, Centre for Stem Cell Research Annual Meeting. 2009.
For the abstract entitled “CML CD34+ cells have reduced uptake of imatinib due to uniformly low OCT-1 activity, which can be increased with diclofenac treatment”, Adelaide, November 2009.

Student Travel Scholarship, The Leukaemia Foundation of Australia. 2008.
Support for students to attend the New Directions in Leukaemia Research Conference. Awarded on the basis of submitted abstracts for work of exceptional novelty and significance. For the abstract entitled “Reduced activity of the OCT-1 protein in primitive CML cells may be a key to stem cell resistance in imatinib treated CML patients”, Sunshine Coast, March 2008.

PhD Scholarship, The Leukaemia Foundation of Australia. 2007-2010.
To provide support for the educational and professional development of researchers and other professionals undertaking a PhD. The award is to support basic, applied and translational research in Australia into the causes, treatment and care of people with leukaemia, lymphoma, myeloma and related blood disorders.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABL</td>
<td>Abelson kinase</td>
</tr>
<tr>
<td>ACD</td>
<td>Anticoagulant Citrate Dextrose Solution Formula A</td>
</tr>
<tr>
<td>ALL</td>
<td>Acute lymphoblastic leukaemia</td>
</tr>
<tr>
<td>AML</td>
<td>Acute myeloid leukaemia</td>
</tr>
<tr>
<td>AP</td>
<td>Accelerated phase</td>
</tr>
<tr>
<td>ATP</td>
<td>Adenosine triphosphate</td>
</tr>
<tr>
<td>BC</td>
<td>Blast crisis</td>
</tr>
<tr>
<td>BCR</td>
<td>Breakpoint cluster region</td>
</tr>
<tr>
<td>BM</td>
<td>Bone marrow</td>
</tr>
<tr>
<td>BSA</td>
<td>Bovine serum albumin</td>
</tr>
<tr>
<td>C</td>
<td>Celcius</td>
</tr>
<tr>
<td>CCR</td>
<td>Complete cytogenetic response</td>
</tr>
<tr>
<td>cDNA</td>
<td>Complementary deoxyribonucleic acid</td>
</tr>
<tr>
<td>CFSE</td>
<td>5-6-carboxyfluorescein diacetate, succinimidyl ester</td>
</tr>
<tr>
<td>CML</td>
<td>Chronic myeloid leukaemia</td>
</tr>
<tr>
<td>CMR</td>
<td>Complete molecular response</td>
</tr>
<tr>
<td>CP</td>
<td>Chronic phase</td>
</tr>
<tr>
<td>CPM</td>
<td>Counts per minute</td>
</tr>
<tr>
<td>CrkI</td>
<td>Crk-like protein</td>
</tr>
<tr>
<td>p-CrkI</td>
<td>Phosphorylated Crk-like protein</td>
</tr>
<tr>
<td>CV</td>
<td>Control vector</td>
</tr>
<tr>
<td>DEPC</td>
<td>Diethyl pyrocarbonate</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulphoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>Deoxyribonucleic acid</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>dNTPs</td>
<td>Deoxynucleotide triphosphates</td>
</tr>
<tr>
<td>DTT</td>
<td>Dithiothreitol</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene diamine tetraacetate</td>
</tr>
<tr>
<td>eGFP</td>
<td>Enhanced green fluorescence protein</td>
</tr>
<tr>
<td>FACS</td>
<td>Fluorescence activated cell sorting</td>
</tr>
<tr>
<td>FITC</td>
<td>Fluorescein isothiocyanate</td>
</tr>
<tr>
<td>FCS</td>
<td>Foetal calf serum</td>
</tr>
<tr>
<td>Hanks</td>
<td>Hanks Balanced Salt Solution</td>
</tr>
<tr>
<td>HSC</td>
<td>Haematopoietic stem cell</td>
</tr>
<tr>
<td>IC50</td>
<td>50% inhibitory concentration</td>
</tr>
<tr>
<td>IFN-α</td>
<td>Interferon alpha</td>
</tr>
<tr>
<td>IM</td>
<td>Imatinib (STI571)</td>
</tr>
<tr>
<td>IRIS</td>
<td>International randomised study of interferon versus STI571</td>
</tr>
<tr>
<td>IUR</td>
<td>Intracellular uptake and retention</td>
</tr>
<tr>
<td>kD</td>
<td>Kilo Dalton</td>
</tr>
<tr>
<td>L</td>
<td>Litre</td>
</tr>
<tr>
<td>M</td>
<td>Molar</td>
</tr>
<tr>
<td>mA</td>
<td>Milli Amp ($10^{-3}$ Amp)</td>
</tr>
<tr>
<td>MACS</td>
<td>Magnetically activated cell sorting</td>
</tr>
<tr>
<td>MCR</td>
<td>Major cytogenetic response</td>
</tr>
<tr>
<td>MMR</td>
<td>Major molecular response</td>
</tr>
<tr>
<td>mM</td>
<td>Milli Molar ($10^{-3}$ Molar)</td>
</tr>
<tr>
<td>MNC</td>
<td>Mononuclear cells</td>
</tr>
<tr>
<td>mRNA</td>
<td>Messenger ribonucleic acid</td>
</tr>
<tr>
<td>μM</td>
<td>Micro Molar ($10^{-6}$ Molar)</td>
</tr>
<tr>
<td>μg</td>
<td>Micro gram ($10^{-6}$ gram)</td>
</tr>
</tbody>
</table>
**ng** Nano gram (10^{-9} gram)

**Nil** Nilotinib (AMN107)

**OA** OCT-1 activity

**OCT-1** Organic cation transporter 1

**PB** Peripheral blood

**PBS** Phosphate Buffered Saline

**PCR** Polymerase chain reaction

**PE** Phycoerythrin

**Ph** Philadelphia chromosome

**PI** Propidium Iodide

**PMA** Phorbol-12-myristate-13-acetate

**PVDF** Polyvinylidene fluoride

**RNA** Ribonucleic acid

**RPM** Revolutions per minute

**RPMI** Roswell Park Memorial Institute (media)

**RT** Room temperature

**RT-PCR** Reverse transcription polymerase chain reaction

**RQ-PCR** Real time quantitative polymerase chain reaction

**SD** Standard deviation

**SDS** Sodium dodecyl sulphate

**SEM** Standard error of the mean

**S/N** Supernatant

**STI571** Signal transduction inhibitor 571 (imatinib)

**TBS** Tris buffered saline

**TBST** Tris buffered saline with 0.1% Tween20

**TKI** Tyrosine kinase inhibitor
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>Units</td>
</tr>
<tr>
<td>UV</td>
<td>Ultraviolet</td>
</tr>
<tr>
<td>v/v</td>
<td>Volume per volume</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cells</td>
</tr>
<tr>
<td>WCC</td>
<td>White cell count</td>
</tr>
<tr>
<td>w/v</td>
<td>Weight per unit volume</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

For anyone who has undertaken the tedious and rewarding challenge of a PhD, it is well recognized that strong guidance and support are essential for survival and success. I have been fortunate in having the support from a large number of individuals, whom without I would not have been able to fulfill this journey.

First and foremost I must thank my three superb supervisors: Professor Tim Hughes, Dr Deb White and A/Professor Andrew Zannettino. Tim for his enthusiasm for data, questions during lab meetings and his valuable ideas. Deb for her unwavering encouragement, patience, guidance and dancing at conferences! Andrew for his unique perspective and the laughter that he could always bring me. And for the entertaining group meetings that always left me feeling happier and more focused, although at times baffled by the hilarity of what went on.

To all the past and present members of the Melissa White Lab, thank you for all the technical assistance and the fun lab environment. I would specifically like to thank Verity Saunders and Amity Frede for their assistance with patient samples, Phuong Dang for being the live troubleshooting guide for PCR, Stephanie Arbon and Sasha Wheeler for their constant efforts in digging up patient data for me and Kelvin Groot-Obbink for bringing quality music to the lab! With a fond grin 😊 I want to thank all the past and present Melissa White Lab students (Laura Eadie, Dale Watkins, Lisa Schafranek, Carine Tang, Jackie Wong, Dr Stephen Blake, Dr David Ross and Dr Devendra Hiwase) for their continuous encouragement, for the quality discussions in the student room (whether they be science-related or not!) and for the essential Friday night drinks!

I must also acknowledge all the other researchers who have provided strong collaborations and assisted me during my candidature. A big thank you to Dr Chuck Bailey and Professor John Rasko, from the Centenary Institute in Sydney, for producing the lentiviral particles which were critical to Chapter 5 of this thesis. To Tom Sullivan, from the University of Adelaide, for his help with statistics. To Sandy McIntyre and Kate Pilkington for their hours of cell sorting and general Flow Cytometry expertise. To Dr Sue Branford, Rebecca Lawrence, Chani Field and Jodi Prime, from Molecular Pathology, for their assistance in BCR-ABL RQ-PCR and sequencing.
To Dr Peter Diamond for his molecular biology expertise and patience in teaching me lentiviral production. To Sharon Paton for her help in morphological analysis. And to Dr Tony Cambareri for his amazing word processing and formatting abilities.

I must make a significant thanks to the Leukaemia Foundation of Australia, for providing me with a generous scholarship for the duration of my PhD. This scholarship enabled me to attend a large number of prestigious national and international conferences and gave me unique opportunities to become involved with fundraising and patient programs. A special thanks to Dr Sue O’Brien for her endless patience with my continual flow of emails and for her genuine excitement of my project and for all my milestones along the way.

Undertaking a PhD is an impossible task without good friends’ along-side to keep you smiling through the toughest of times. I thank all my friends who have stood by me and endured my complaints and moods. Special mention must go to Stephanie Zrim and Emma Gordon who were both outstanding in this regard. I also wish to make a sincere thanks to Jase Sims for his love and humour, which kept me smiling and optimistic during the early years of my PhD.

A heart-felt thanks to my Mum and Dad (Sue and Neil), my brothers Dale and Grant and to all of my extended family. Who were unwavering in their belief that I would succeed, and more importantly were always there to support, to listen and to share my excitement over successful experiments, manuscripts and conferences.

Lastly, my deepest thanks goes to my partner Derek Bredl. His love, empathy, affection and relentless support have been my smiles, comfort, peace and strength over the past couple years. And to his gorgeous family (Mackenzie, Dana, Tammy, David, Georgia and Hunter) who have embraced and supported me, I thank you for the joy you have brought into my life.
ABSTRACT

Despite the excellent responses observed in patients with chronic phase (CP) chronic myeloid leukaemia (CML) on imatinib therapy, approximately 25% display primary resistance or sub-optimal response. The organic cation transporter 1 (OCT-1) is the major active influx pump for imatinib in CML cells. The functional OCT-1 activity in mononuclear cells (MNC) is highly variable between patients and significantly correlates with a patient’s molecular response to imatinib treatment and overall survival. Given the strong predictive value of OCT-1 activity, the present study was aimed at identifying factors responsible for the variation in OCT-1 activity seen in patients.

Pure populations of neutrophils, monocytes and lymphocytes were isolated from the peripheral blood of CML patients at diagnosis. The OCT-1 activity and OCT-1 mRNA expression was found to be the highest in the neutrophil population, followed by monocytes then lymphocytes. When the surface expression of the granulocytic antigens CD15 and CD16 were examined, a significant correlation was observed between MNC OCT-1 activity and the proportion of immature myeloid cells expressing CD15+16-. Interestingly, the neutrophil OCT-1 activity was found to be similar when recovered from CML patients at diagnosis, CML patients in cytogenetic remission and normal donors, implying that BCR-ABL expression is unlikely to influence OCT-1 activity. This hypothesis was confirmed in a cell line model, in which ectopic BCR-ABL expression was not found to directly affect OCT-1 expression or function, but stimulated myeloid differentiation which, in turn, led to increased OCT-1 activity. These data suggest that the predictive MNC OCT-1 activity is most strongly related to cell lineage, particularly the proportion of immature myeloid cells, but is not directly related to BCR-ABL.
CML early progenitor cells are less sensitive to imatinib induced apoptosis and are likely contributors to disease persistence. It was found that the OCT-1 activity and OCT-1 mRNA expression was significantly lower in primitive CD34+ cells compared with mature CD34- cells recovered from CML patients. These results indicate that low imatinib accumulation in primitive CML cells may be a critical determinant of long-term disease persistence. Studies to investigate whether the MNC OCT-1 activity provides a surrogate indicator of effective targeting of the more immature CD34+ cells failed to identify a relationship between high CD34+ OCT-1 activity and the achievement of major molecular response. This is despite the confirmation of previous findings that high MNC OCT-1 activity is significantly associated with the achievement of major molecular response to imatinib treatment. These important findings suggest that kinase inhibition in these mature cells, and not the CD34+ cells, may be the key determinant of response in CML.

In conclusion, the studies outlined in this thesis have identified cell lineage as a key contributor to MNC OCT-1 activity and hence response to imatinib treatment. While primitive CD34+ cells demonstrate low OCT-1 activity, which may contribute to their persistence despite imatinib therapy, the OCT-1 activity in these cells does not correlate with patient response to treatment. Therefore, direct targeting of this primitive population may not be essential for achievement of early and deep molecular responses.